NASDAQ:INGN - Inogen Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $73.50
  • Forecasted Upside: 49.24 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$49.25
▲ +0.68 (1.40%)

This chart shows the closing price for INGN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Inogen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INGN

Analyst Price Target is $73.50
▲ +49.24% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Inogen in the last 3 months. The average price target is $73.50, with a high forecast of $75.00 and a low forecast of $72.00. The average price target represents a 49.24% upside from the last price of $49.25.

This chart shows the closing price for INGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Inogen. This rating has held steady since February 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 1 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/21/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/20/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/8/2021Needham & Company LLCReiterated RatingHoldMedium
7/20/2021SVB LeerinkReiterated RatingMarket PerformMedium
6/4/2021William BlairUpgradeMarket Perform ➝ OutperformHigh
5/5/2021SVB LeerinkBoost Price TargetMarket Perform$67.00 ➝ $72.00High
5/5/2021KeyCorpBoost Price TargetPositive ➝ Overweight$60.00 ➝ $75.00High
2/25/2021SVB LeerinkBoost Price TargetMarket Perform$47.00 ➝ $54.00High
12/14/2020KeyCorpUpgradeSector Weight ➝ Overweight$60.00High
11/13/2020Needham & Company LLCReiterated RatingHoldMedium
8/5/2020SVB LeerinkLower Price TargetMarket Perform$42.00 ➝ $35.00High
7/23/2020Needham & Company LLCDowngradeBuy ➝ HoldHigh
6/10/2020William BlairDowngradeOutperform ➝ Market PerformHigh
6/1/2020SVB LeerinkBoost Price TargetMarket Perform$42.00 ➝ $56.00Medium
5/6/2020SVB LeerinkLower Price TargetMarket Perform$68.00 ➝ $56.00High
5/6/2020Needham & Company LLCLower Price TargetBuy$80.00 ➝ $75.00High
2/26/2020JPMorgan Chase & Co.Lower Price TargetUnderweight$60.00 ➝ $45.00High
12/20/2019JPMorgan Chase & Co.Boost Price TargetUnderweight$47.50 ➝ $60.00Low
11/22/2019Needham & Company LLCReiterated RatingBuy$90.00Low
11/6/2019Needham & Company LLCUpgradeHold ➝ Buy$90.00Medium
8/8/2019SVB LeerinkReiterated RatingOutperform ➝ Market Perform$78.00 ➝ $47.00High
8/7/2019KeyCorpReiterated RatingHoldMedium
8/7/2019Piper Jaffray CompaniesLower Price TargetOverweight$140.00 ➝ $80.00High
8/7/2019Stifel NicolausDowngradeBuy ➝ Hold$85.00 ➝ $48.00High
8/7/2019Needham & Company LLCDowngradeBuy ➝ HoldLow
7/3/2019JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$72.00Low
6/28/2019Needham & Company LLCDowngradeStrong-Buy ➝ Buy$111.00 ➝ $91.00High
5/8/2019Stifel NicolausLower Price TargetBuy$160.00 ➝ $85.00High
5/8/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$175.00 ➝ $72.00High
5/8/2019Needham & Company LLCLower Price TargetStrong-Buy ➝ Strong-Buy$191.00 ➝ $111.00Medium
4/9/2019Needham & Company LLCReiterated RatingBuy$191.00Low
2/27/2019JPMorgan Chase & Co.Lower Price TargetPositive ➝ Overweight$175.00High
2/27/2019Piper Jaffray CompaniesLower Price TargetOverweight$290.00 ➝ $185.00High
2/27/2019Needham & Company LLCReiterated RatingStrong-Buy ➝ Strong-Buy$280.00 ➝ $191.00High
11/26/2018Needham & Company LLCBoost Price TargetBuy ➝ Strong-Buy$280.00Low
11/20/2018Needham & Company LLCUpgradeBuy ➝ Strong-Buy$280.00 ➝ $280.00High
11/7/2018Needham & Company LLCReiterated RatingBuy$296.00 ➝ $280.00High
9/12/2018Piper Jaffray CompaniesBoost Price TargetOverweight$245.00 ➝ $290.00Medium
9/10/2018Needham & Company LLCDowngradeStrong-Buy ➝ Buy$254.00 ➝ $296.00Low
8/21/2018Stifel NicolausSet Price TargetBuy$258.00Medium
8/8/2018Needham & Company LLCBoost Price TargetStrong-Buy$215.00 ➝ $254.00High
8/7/2018Piper Jaffray CompaniesBoost Price TargetOverweight$245.00High
7/9/2018Piper Jaffray CompaniesBoost Price TargetOverweight$235.00High
6/13/2018Needham & Company LLCReiterated RatingBuyLow
6/6/2018KeyCorpInitiated CoverageEqual WeightLow
5/1/2018SVB LeerinkReiterated RatingOutperform$150.00 ➝ $170.00High
5/1/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$150.00 ➝ $180.00High
5/1/2018Needham & Company LLCBoost Price TargetStrong-Buy ➝ Strong-Buy$150.00 ➝ $215.00Low
4/30/2018Piper Jaffray CompaniesBoost Price TargetOverweight$190.00High
4/14/2018Piper Jaffray CompaniesSet Price TargetBuy$145.00Low
3/27/2018Needham & Company LLCReiterated RatingBuy$150.00High
2/28/2018Needham & Company LLCBoost Price TargetStrong-Buy ➝ Strong-Buy$125.00 ➝ $150.00High
2/20/2018Piper Jaffray CompaniesUpgradeNeutral ➝ OverweightMedium
11/8/2017SVB LeerinkReiterated RatingOutperform$115.00 ➝ $120.00N/A
11/8/2017Needham & Company LLCBoost Price TargetStrong-Buy$108.00 ➝ $125.00N/A
9/12/2017Piper Jaffray CompaniesReiterated RatingHold$90.00Low
9/1/2017Needham & Company LLCReiterated RatingBuy$108.00Medium
6/26/2017JPMorgan Chase & Co.Boost Price TargetOverweight$102.00Low
6/9/2017Needham & Company LLCBoost Price TargetStrong-Buy$96.00 ➝ $108.00Low
6/8/2017Needham & Company LLCLower Price TargetStrong-Buy$108.00 ➝ $96.00High
5/10/2017Stifel NicolausBoost Price TargetHold ➝ Hold$65.00 ➝ $75.00High
5/10/2017Needham & Company LLCReiterated RatingBuy$96.00High
4/18/2017SidotiInitiated CoverageNeutral ➝ Neutral$79.00Medium
4/5/2017Needham & Company LLCReiterated RatingBuy$83.00Medium
3/1/2017JPMorgan Chase & Co.Set Price TargetBuy$78.00N/A
3/1/2017Stifel NicolausBoost Price Target$65.00N/A
3/1/2017Needham & Company LLCBoost Price TargetStrong-Buy$78.00 ➝ $83.00N/A
1/19/2017Needham & Company LLCBoost Price TargetStrong-Buy$66.00 ➝ $78.00N/A
1/19/2017Needham & Company LLCInitiated CoverageStrong-BuyN/A
11/4/2016Needham & Company LLCBoost Price TargetStrong-Buy$64.00 ➝ $66.00N/A
(Data available from 9/19/2016 forward)

News Sentiment Rating

0.25 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/21/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/22/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/22/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/21/2021
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/21/2021
  • 2 very positive mentions
  • 19 positive mentions
  • 2 negative mentions
  • 6 very negative mentions
8/20/2021
  • 3 very positive mentions
  • 12 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
9/19/2021

Current Sentiment

  • 3 very positive mentions
  • 12 positive mentions
  • 4 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Inogen logo
Inogen, Inc. engages in the development, manufacture, and marketing of portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its products consists of Inogen One G4 system, Inogen One G3 system, Inogen One G5 system, Inogen TAV, and Inogen at Home. The company was founded by Alison Perry, Alison K. Bauerlein, Brenton Taylor, and Byron Myers on November 27, 2001 and is headquartered in Goleta, CA.
Read More

Today's Range

Now: $49.25
Low: $48.41
High: $49.65

50 Day Range

MA: $63.68
Low: $48.51
High: $82.26

52 Week Range

Now: $49.25
Low: $26.90
High: $82.35

Volume

612,916 shs

Average Volume

201,117 shs

Market Capitalization

$1.11 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.9

Frequently Asked Questions

What sell-side analysts currently cover shares of Inogen?

The following equities research analysts have issued research reports on Inogen in the last twelve months: KeyCorp, Needham & Company LLC, SVB Leerink LLC, TheStreet, William Blair, and Zacks Investment Research.
View the latest analyst ratings for INGN.

What is the current price target for Inogen?

2 Wall Street analysts have set twelve-month price targets for Inogen in the last year. Their average twelve-month price target is $73.50, suggesting a possible upside of 49.2%. KeyCorp has the highest price target set, predicting INGN will reach $75.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $72.00 for Inogen in the next year.
View the latest price targets for INGN.

What is the current consensus analyst rating for Inogen?

Inogen currently has 2 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe INGN will outperform the market and that investors should add to their positions of Inogen.
View the latest ratings for INGN.

What other companies compete with Inogen?

How do I contact Inogen's investor relations team?

Inogen's physical mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The medical technology company's listed phone number is (805) 562-0500 and its investor relations email address is [email protected] The official website for Inogen is www.inogen.com.